[Pharmacologic aspects of thrombophilia].
Thrombophilic conditions are due to a failure of antithrombotic mechanisms. Starting from this fact, the possibilities of influencing pharmacologically disturbances of biosynthesis and function of prostacyclin and plasminogen activator of the vessel wall as well as of plasmatic inhibitors of clotting factors were discussed. The results of experimental and clinical studies were reported.
D000925:Anticoagulants / Q000627:therapeutic use*; D000990:Antithrombin III / Q000627:therapeutic use; D020152:Antithrombin III Deficiency; D001779:Blood Coagulation Factors / Q000378:metabolism; D001780:Blood Coagulation Tests; D011464:Epoprostenol / Q000097:blood; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D010960:Plasminogen Activators / Q000378:metabolism; D010974:Platelet Aggregation / Q000187:drug effects; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D000990:Antithrombin III; D011464:Epoprostenol; D010960:Plasminogen Activators
Pharmakologische Aspekte der Thrombophilie.